PHAXIAM Therapeutics (PHXM) Competitors $3.10 0.00 (0.00%) As of 04/24/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock PHXM vs. VRCA, XLO, SPRO, RNTX, STTK, ATNM, ATRA, RVPH, LTRN, and BLUEShould you be buying PHAXIAM Therapeutics stock or one of its competitors? The main competitors of PHAXIAM Therapeutics include Verrica Pharmaceuticals (VRCA), Xilio Therapeutics (XLO), Spero Therapeutics (SPRO), Rein Therapeutics (RNTX), Shattuck Labs (STTK), Actinium Pharmaceuticals (ATNM), Atara Biotherapeutics (ATRA), Reviva Pharmaceuticals (RVPH), Lantern Pharma (LTRN), and bluebird bio (BLUE). These companies are all part of the "pharmaceutical products" industry. PHAXIAM Therapeutics vs. Verrica Pharmaceuticals Xilio Therapeutics Spero Therapeutics Rein Therapeutics Shattuck Labs Actinium Pharmaceuticals Atara Biotherapeutics Reviva Pharmaceuticals Lantern Pharma bluebird bio PHAXIAM Therapeutics (NASDAQ:PHXM) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends. Which has higher valuation & earnings, PHXM or VRCA? PHAXIAM Therapeutics has higher revenue and earnings than Verrica Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPHAXIAM Therapeutics$32.66M0.32-$240KN/AN/AVerrica Pharmaceuticals$7.57M5.93-$67M-$1.54-0.32 Does the media favor PHXM or VRCA? In the previous week, PHAXIAM Therapeutics and PHAXIAM Therapeutics both had 1 articles in the media. Verrica Pharmaceuticals' average media sentiment score of 1.87 beat PHAXIAM Therapeutics' score of 0.00 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment PHAXIAM Therapeutics Neutral Verrica Pharmaceuticals Very Positive Do analysts recommend PHXM or VRCA? Verrica Pharmaceuticals has a consensus price target of $9.50, indicating a potential upside of 1,842.34%. Given Verrica Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than PHAXIAM Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Verrica Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 Is PHXM or VRCA more profitable? PHAXIAM Therapeutics has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -625.06%. PHAXIAM Therapeutics' return on equity of 0.00% beat Verrica Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets PHAXIAM TherapeuticsN/A N/A N/A Verrica Pharmaceuticals -625.06%-591.84%-141.63% Does the MarketBeat Community believe in PHXM or VRCA? Verrica Pharmaceuticals received 167 more outperform votes than PHAXIAM Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformPHAXIAM TherapeuticsN/AN/AVerrica PharmaceuticalsOutperform Votes16763.26% Underperform Votes9736.74% Which has more volatility and risk, PHXM or VRCA? PHAXIAM Therapeutics has a beta of 2.35, suggesting that its share price is 135% more volatile than the S&P 500. Comparatively, Verrica Pharmaceuticals has a beta of 1.68, suggesting that its share price is 68% more volatile than the S&P 500. Do institutionals & insiders hold more shares of PHXM or VRCA? 0.4% of PHAXIAM Therapeutics shares are held by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 1.9% of PHAXIAM Therapeutics shares are held by company insiders. Comparatively, 42.6% of Verrica Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryVerrica Pharmaceuticals beats PHAXIAM Therapeutics on 8 of the 14 factors compared between the two stocks. Get PHAXIAM Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PHXM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHXM vs. The Competition Export to ExcelMetricPHAXIAM TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.58M$120.35M$5.44B$7.80BDividend YieldN/A3.69%5.43%4.31%P/E RatioN/A3.0022.1418.40Price / Sales0.324,221.44389.71101.29Price / CashN/A13.0238.2034.62Price / Book0.3934.746.664.18Net Income-$240,000.00-$90.45M$3.21B$247.71M7 Day PerformanceN/A4.06%6.21%6.61%1 Month PerformanceN/A-0.48%-2.82%-2.21%1 Year PerformanceN/A88.73%16.44%4.68% PHAXIAM Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049News CoverageVRCAVerrica Pharmaceuticals3.3634 of 5 stars$0.46-2.0%$9.50+1,971.1%-92.6%$42.10M$7.57M-0.2540XLOXilio Therapeutics2.1184 of 5 stars$0.79-2.0%$4.00+403.8%-18.0%$41.10M$6.34M-0.4670Negative NewsSPROSpero Therapeutics4.1159 of 5 stars$0.73-0.7%$5.00+587.7%-49.3%$40.93M$27.40M10.39150Positive NewsRNTXRein TherapeuticsN/A$1.86+0.5%N/AN/A$40.91MN/A-0.609Analyst RevisionGap DownSTTKShattuck Labs2.0304 of 5 stars$0.85-4.7%$7.50+781.0%-91.9%$40.78M$5.72M-0.56100Upcoming EarningsPositive NewsATNMActinium Pharmaceuticals1.2535 of 5 stars$1.30-5.8%$7.40+469.2%N/A$40.56M$81,000.00-0.9430Gap DownATRAAtara Biotherapeutics4.2896 of 5 stars$6.90+2.4%$17.75+157.2%-58.2%$40.43M$128.94M-0.27330News CoveragePositive NewsRVPHReviva Pharmaceuticals2.2852 of 5 stars$0.86+13.5%$10.00+1,059.2%-71.3%$40.32MN/A-0.785Analyst ForecastNews CoverageLTRNLantern Pharma1.7177 of 5 stars$3.73+8.1%$25.00+570.2%-34.2%$40.23MN/A-2.1020Positive NewsBLUEbluebird bio2.2787 of 5 stars$4.09-5.8%$44.60+990.5%-77.2%$40.04M$83.81M-0.11520 Related Companies and Tools Related Companies Verrica Pharmaceuticals Competitors Xilio Therapeutics Competitors Spero Therapeutics Competitors Rein Therapeutics Competitors Shattuck Labs Competitors Actinium Pharmaceuticals Competitors Atara Biotherapeutics Competitors Reviva Pharmaceuticals Competitors Lantern Pharma Competitors bluebird bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHXM) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PHAXIAM Therapeutics S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share PHAXIAM Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PHXM Stock Free PHXM Stock Alerts